According to a recent medical journal article, acute renal failure (ARF), or kidney failure, is reported as an adverse drug reaction 5.7 times more frequently with Uloric (febuxostat) than with other urate-lowering therapy (ULT) gout drugs, and 3.3 times more often with allopurinol. This is some important new Uloric drug safety information from our perspective.
This article, “Acute Kidney Injury Associated With Febuxostat and Allopurinol — A Post-Marketing Study”, was published by the Arthritis Research & Therapy medical journal in November 2019. The new Uloric drug safety information in that article is summarized in this excerpt:
In the present study, we detected a disproportionality signal for [acute renal failure (ARF)] and the ULTs [Uloric (febuxostat)] and allopurinol. The presence of this signal was confirmed in a variety of sensitivity analyses (i.e., when [Uloric (febuxostat)] and allopurinol were the only suspected drugs, when we used other [Xanthine oxydase (XO)] inhibitors as the comparator or when known nephrotoxic drugs were excluded).
…. Until the present case/non-case study, the risk of [acute kidney injury (AKI)] associated with allopurinol and [Uloric (febuxostat)] had been underestimated.
We will continue to monitor the FDA and review medical journals for any significant developments concerning this new Uloric drug safety information about acute kidney injury (AKI) and acute renal failure (ARF).
Our law firm is investigating possible Uloric lawsuits where patients have suffered Uloric side effects.[View article at original source]